#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Biotinidase deficiency Hypergammaglobulinaemia benign monoclonal Brain abscess Isodicentric chromosome 15 syndrome Alpha-1 antitrypsin deficiency Atopic keratoconjunctivitis Polyneuropathy Hydrocephalus Hypersensitivity pneumonitis High-grade B-cell lymphoma Phenylketonuria Bladder cancer Cerebral amyloid angiopathy Urethral valves Spinal cord injury cervical More trials…

    Learn about Rare Diseases

    Phenylketonuria Isodicentric chromosome 15 syndrome Advanced systemic mastocytosis – Life with Disease Glomerulonephritis membranous – Life with Disease Mastocytosis – Life with Disease Haemophilia A with anti factor VIII – Trials in Disease Indolent systemic mastocytosis – Basic Information Pemphigus – Life with Disease Small intestine leiomyosarcoma – Diagnostics Antisynthetase syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Adg126 Clindamycin Hydrochloride Ixazomib GAXILOSE VX-407 Sasanlimab Talquetamab Benzylpenicillin Asciminib Hydrochloride Oxacillin Triamcinolone Acetonide Tuvusertib Cariprazine VG801-2 Fidanacogene Elaparvovec Ict01 Avelumab Colestyramine Odm-212 Aficamten More therapies…

    Learn about Your Condition

    Keratosis follicular Uveal melanoma Hepatic cancer Diabetic foot infection Gastric cancer stage IV Colour blindness Constipation Corneal graft rejection Depression Upper limb fracture Psychotic disorder Neurotrophic keratopathy Bacterial vaginosis Haemodialysis Psoriasis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopital Saint Antoine

Hopital Saint Antoine

184 Rue Du Faubourg Saint Antoine, Paris, 75571, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Secukinumab
    Belgium Czechia France Germany Hungary Italy +3

  • Study of Dazostinag and Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Dazostinag
    Austria Belgium France Poland

  • Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Paclitaxel
    • Ramucirumab
    • Trastuzumab Deruxtecan
    Belgium France Germany Hungary Ireland Italy +4

  • Study on EO4010 Vaccine with Nivolumab and Bevacizumab for Patients with Metastatic Colorectal Cancer Who Have Already Received Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Eo2317
    • Eo2318
    France Spain

  • Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Belgium Czechia France Germany Greece Italy +3

  • Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Bortezomib
    • Carfilzomib
    • Dexamethasone
    Austria Belgium Czechia Denmark France Germany +7

  • Study of benralizumab compared to placebo for treatment of patients with Hypereosinophilic Syndrome (HES)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hypereosinophilic syndrome
    Investigated Drugs:
    • Benralizumab
    Austria Belgium Denmark France Germany Italy +3

  • Study on Deucrictibant and Icatibant for Treating Hereditary Angioedema Attacks in Adolescents and Adults

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Deucrictibant
    • Icatibant
    Austria Bulgaria Czechia France Germany Hungary +8

  • Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    • Tiragolumab
    Belgium France Germany Italy Poland Spain

  • Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Brentuximab Vedotin
    • Lenalidomide
    • Rituximab
    Belgium Czechia Denmark France Italy Poland +1
Previous Page
1 … 11 12 13 14 15
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!